Sage Therapeutics, Inc. (SAGE) EPS Estimated At $-1.85 on May, 8

April 17, 2018 - By Sheila Anderson

Sage Therapeutics, Inc. (NASDAQ:SAGE) Corporate Logo
Big Money Sentiment increased to 1.49 in 2017 Q4. It has change of 0.28, from 2017Q3’s 1.21. The ratio increased due to Sage Therapeutics, Inc. positioning: 27 sold and 56 reduced. 63 funds acquired stakes and 61 increased stakes. Investors holded 38.55 million in 2017Q3 but now own 41.45 million shares or 7.53% more.
Putnam Invests Limited Company reported 5,983 shs. Zeke Advsr Ltd holds 0.03% or 1,949 shs. 29,236 are held by Century Companies. Atika Cap Mgmt Lc has invested 0.38% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Metropolitan Life Insurance holds 0.03% or 11,752 shs. Wellington Gru Llp holds 0.08% or 2.07 million shs. Glob X Mgmt Ltd Liability Co accumulated 318 shs. Jane Street Grp holds 0.01% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 14,872 shs. Palo Alto Investors Ltd Liability Co reported 810,806 shs or 5.75% of all its holdings. Qs Lc, New York-based fund reported 805 shs. Emerald Advisers Pa reported 168,785 shs or 1.07% of all its holdings. 13,322 were accumulated by Teacher Retirement System Of Texas. New Leaf Venture Ptnrs Ltd Liability Corp has 1.93% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Pacad Limited accumulated 0.03% or 800 shs. 3,908 were accumulated by Boothbay Fund Mngmt Llc.

Sage Therapeutics, Inc. had 3 sales and 0 insider purchases since December 14, 2017. This’s net activity of $27.36 million. PAUL STEVEN M sold $10.00M worth of stock or 58,139 shs. The insider Robichaud Albert sold $9.57M.

On May, 8 Sage Therapeutics, Inc. (NASDAQ:SAGE)’s earnings release is anticipated by WallStreet, Faxor reports. EPS of $-1.85 is 21.71 % down from 2017’s $-1.52 EPS. 5.71 % negative EPS growth is what Wall Street’s predicts after $-1.75 reported EPS last quarter. On during the last trading session the stock decreased $7.63 or 4.47%, reaching $162.95.Sage Therapeutics, Inc. has volume of 387,458 shares. Since April 17, 2017 SAGE has risen 135.95% and is uptrending. SAGE outperformed the S&P 500 by 124.40%.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

In total 11 analysts cover SAGE Therapeutics (NASDAQ:SAGE). “Buy” rating has 11, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 23 are the (NASDAQ:SAGE)’s analyst reports since October 19, 2017 according to StockzIntelligence Inc. In Friday, November 10 report Chardan Capital Markets upgraded the stock to “Buy” rating. On Thursday, October 19 SunTrust maintained the shares of SAGE in report with “Buy” rating. On Thursday, November 2 the firm has “Buy” rating by Stifel Nicolaus given. On Thursday, November 9 the firm earned “Buy” rating by RBC Capital Markets. The company rating was maintained by BMO Capital Markets on Thursday, November 9. On Monday, March 26 the rating was maintained by Canaccord Genuity with “Buy”. On Friday, November 17 the company was maintained by BMO Capital Markets. On Thursday, December 7 the firm earned “Buy” rating by BMO Capital Markets. In Thursday, December 7 report SunTrust maintained it with “Buy” rating and $178.0 target. On Thursday, October 26 BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) with “Buy” rating.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders.The firm is valued at $7.46 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD).Currently it has negative earnings. The company's product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson's diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.